Neuro exam 1 part 2 Flashcards
Hematology (145 cards)
Pathophysiology of MS
- MS is a disease which results in neurologic dysfunction due to degradation of myelin
- o Myelin is fatty substance which surrounds the nerve axon allowing signal to be transmitted from one location in the CNS to another distant location with greater speed and efficiency
- • This autoimmune process causes focal areas of demyelination with associated inflammation that slows down or completely interrupts transmission of neural activity
MS is a life-long disease which presents in what two distinct forms
Relapsing Remitting MS (RRMS)
- ▪ This is the most common form of MS and is defined as distinct acute exacerbations of demyelinating disease that result in transient neurologic dysfunction lasting days to weeks, before typically resolving completely, leaving the patient at or very near to their previous neurologic baseline
- ▪ RRMS accounts for >90% of all MS cases
- Patients with longstanding RRMS will often transition into a Secondary Progressive MS (SPMS) disease category many years after initial symptom onset
- • SPMS is defined as incomplete return to baseline in patients following exacerbation with a history of longstanding RRMS.
- • Approximately half of RRMS will become SPMS at some point.
Primary Progressive MS (PPMS)
- ▪ PPMS is the rarer form of MS and is defined as distinct acute exacerbations of demyelinating disease that result in permanent neurologic dysfunction. The patient may show some subtle signs of improvement but they fail to return to their previous neurologic baseline
Epidemiology and Risk factors of MS
MS affects greater than 350,000 patients in the US alone
- o Prevalence of ~10-20/100,000 in the population
• There are clear associations with both genetics and environment
- o Individuals in northern climates develop MS at a strikingly high frequency than those who were raised in southern areas
- ▪ Some postulate a link to Vit. D deficiency but this has never been fully supported in the literature
- Onset of symptoms is typically noted between the ages of 20 and 40, but the disease can occur at nearly any age.
- Females carry a 2-3x risk of developing MS compared to males
- Those with first degree relatives carry a 20-40x risk of developing disease compared to general population
- o There is also a slightly elevated risk of developing MS if other autoimmune diseases are present in first degree relatives
Prototypical presentations of MS
I will begin this section with the preface that MS can present with nearly any imaginable neurologic impairment, ranging from monocular blindness to ataxia to tremor to even quadriplegia. The disease examples below represent the most common initial presentations of demyelinating diseases and are by no means all encompassing. I am specifically seeking to provide the most frequently seen and tested clinical presentations so that you will be familiar with them when they encountered in the clinic or in a question stem.
- Optic Neuritis
- Intranuclear opthalmoplegia (INO)
- Transverse myelitis
Define the clinical features of optic neuritis,
Optic Neuritis
o Very common clinical syndrome resulting from MS
o This is defined as acute demyelination of the optic nerve
- ▪ Typical anterior to the chiasm and only involving one of the optic nerves (left or right), but has been known to involve both nerves and/or the chiasm in rarer presentations
- ▪ Symptoms of a typical optic neuritis are as follows:
- Gradually progressive monocular vision loss often described as hazing or blurring. Many patients will described the sensation of looking through “dirty dishwater” or a “dense screen”
- o Symptoms usually worsen over hours to a day
- o If vision loss is very abrupt (i.e. over seconds to a minute) you should be thinking vascular (stroke of the retina) not demyelinating
- • There is loss of brightness and clarity of color. This is termed color desaturation.
- • Patients will often described a dull ache when looking up, down, left or right.
▪ Exam findings will be remarkable for an afferent pupillary defect and decreased visual acuity in the affected eye. One may also appreciate optic disc edema on funduscopic exam, but this usually takes a couple of days following symptom onset to be readily apparent.
▪ Symptoms usually resolve to previous baseline within weeks, but the afferent pupillary defect may remain a permanent exam finding
Describe features of intranuclear ophthalmoplegia (INO)
o An INO results from a lesion within the brainstem, most specifically within the pons.
o INO is defined as an impairment in horizontal gaze where the affect side has failure of medial gaze (towards the nose) when looking away from the side of the lesion (see below)
- ▪ The INO results from a disconnection of the abducens nucleus to the oculomotor nucleus due to demyelinating disease occurring in the medial longitudinal fasciculus (MLF). The impaired connection results in dis-conjugate gaze with nystagmus in the good eye
Describe clinical features of transverse myelitis
Transverse Myelitis
- o Transverse Myelitis is demyelination of the spinal cord.
- o As you may recall the spinal cord is formed by various tracks, which house fibers with vastly different functions (i.e. corticospinal fibers carry motor input from the brain to the body). Keeping this knowledge of spinal cord anatomy in mind, you will understand why a transverse myelitis can result in a wide ranging of neurologic symptoms ranging from hemi-sided weakness, sensory deficit (of different types), bowel/bladder dysfunction or some combination of all of the above depending on the location and size of the demyelinating plaque.
Diagnosis of MS
- No single test of clinical feature in isolation is significant enough to establish or exclude the diagnosis of MS
- MS often requires extensive history, neuroimaging, and at times additional work-up with cerebrospinal fluid analysis, and prolonged clinical monitoring to establish the diagnosis.
- The diagnosis of MS hinges on the principal of “separation of lesions in time and space”
- o The diagnosis of MS is reliant on a patient having more than one clinical symptom which is consistent with demyelinating disease. These clinical symptoms must be separated in time. It also is necessary that those two or more clinical symptoms localize to different places in the central nervous system
The term “separated in time and space” is the main principal for the McDonald Criteria which is used to clinically make the diagnosis.
o A single episode of demyelinating disease without history of prior transient neurologic deficit is considered a clinically isolated syndrome. This is NOT diagnostic for MS (only a single clinical event, not multiple as is required by the McDonald Criteria), however there is most certainly an increased risk that the patient will develop MS in the next five years compared to the baseline population.
- ▪ Frequent monitoring and follow-up MRI is important in patients who have had a clinically isolated syndrome so that the diagnosis of MS is not delayed.
o Neuroimaging and CSF studies are also helpful in making the diagnosis, but are not a required element in the McDonald Criteria to definitively diagnose MS
• Neuroimaging is mainly focused on the results of magnetic resonance imaging (MRI) rather than CT. In general CT imaging is not helpful in diagnosing MS.
- o MRI’s give very detailed imaging that can reveal current as well as older evidence of demyelination which is extremely useful in supporting the diagnosis of MS
- o Typical features present on MRI include multiple ovoid or confluent white (hyper- intense) areas on the T2 Flair sequence that are often location along the ventricles, corpus callosum, in the brainstem, and cerebellum.
Cerebrospinal Fluid Analysis
o Obtaining CSF and analyzing is for the presence of abnormalities that can be seen in MS can aid in establishing the diagnosis, but are not diagnostic in isolation (meaning it’s just one “piece of the pie” that can support the conclusion that MS is the etiology of the patient’s symptoms
o Abnormalities which can be seen in the CSF of a patient with MS include: oligoclonal banding, abnormally high IgG/albumin ratio, and elevated IgG synthesis rate
o The CSF findings are often absent early in the disease course and present only in approximately 80% of those who suffer with MS
▪ Key point: If the findings of abnormal CSF are present they are helpful, if they are absent it definitely does not exclude the diagnosis of MS.
Treatment options of MS
**Acute exacerbation
Treatment of the acute exacerbation
- o When a patient presents with an acute MS exacerbation, which may clinically appear as an optic neuritis, intranuclear ophthalmoplegia, transverse myelitis or any number of other neurologic deficits, one must keep in mind the basic pathophysiology of the underlying disease. Specifically you must remember that inflammation around the affected part of the nerve is large component of what contributes to the clinical presentation
- o Understanding the role that inflammation plays helps to rationalize why we use high dose corticosteroids to treat MS flare-ups.
- Although we know that patients who have RRMS do get better on their own, often returning to their previous neurologic baseline within weeks to months, we also know that offering treatment with steroids will likely increase the speed of recovery significantly.
- o Typically patients are given 3-5 days of very high dose IV methylprednisolone treatment at the onset of certain significantly symptomatic MS exacerbations such as those clinical presentations listed above. More minor complaints, such as mild sensory impairments, may be treated with lower doses of oral steroids or just monitored clinically for resolution on their own as the risk of side effects from the steroids does not outweigh the benefits of a more rapid recovery
Selected long term treatment of MS
The theory that MS is an inflammatory autoimmune condition guides the mechanisms of action for the available disease modifying therapies.
o These drugs only work in the setting of relapsing remitting MS; there are no available treatments to alter the course of primary progressive MS at this time.
o There are six main disease modifying therapies available to treat MS (three of which are interferon beta agents)
Interferon beta treatments
- ▪ The exact mechanisms for the interferon beta agents are unknown aside for some action on decreasing T-cell migration. All interferon therapies have been shown to decrease the number of clinical exacerbations and to slow the creation of new T2 Flair hyper-intense lesions in the brain. The interferon beta agents are detailed below.
- ▪ Individual drugs (no need to memorize)
- • Interferon beta-1b (Betaseron™)-subcutaneous injection 3x weekly
- • Interferon beta 1a (Rebif™)- subcutaneous injection 3x weekly
- • Interferon beta 1a (Avonex™)-intramuscular injection 1x weekly
- o Less efficacious in aggressive disease compared to the above two choices
- ▪ All the interferon treatments have side effects of flu-like symptoms (headaches, arthralgia, myalgia, and injection site reactions.)
Glatiramer Acetate (Copaxone™)
- ▪ This drug most likely acts in the inflammatory process by interacting at the level of the major histocompatibility complex.
- ▪ Given as a daily subcutaneous injection
- ▪ Fewer side effects than the interferons betas, but this drug is also found to be less effective in aggressive disease compared to the subcutaneously administered interferon beta drugs
o Gilenya (Fingolimod™)
- ▪ It binds to certain sphingosine-1-phosphate receptors which may sequester some lymphocytes in the lymph node and prevent them from entering the brain
- Early trials show it to be as efficacious as the interferon beta treatments
- ▪ Can cause significant bradycardia and hypotension in some patients with the first dose therefore the patient must be monitored in physician’s office or hospital based setting for this reason
o Teriflunomide (Aubagio™)
- ▪ Limits an enzyme in pyrimidine synthesis pathway in lymphocytes which blocks proliferation of activated T and B cells which are responsible for the inflammation in MS
- ▪ Can result in teratogenicity. If patient becomes pregnant it must be removed from system with cholestyramine- Pregnancy category X
- ▪ Common side effects: Diarrhea, nausea, alopecia (resets hair cycle),risk of hepatotoxicity.
o Dimethyl Fumarate (Tecfidera ™)
- ▪ Activates the Nrf2 pathway which is involved in the cellular response to oxidative stress
- ▪ Common side effects: Flushing, diarrhea, nausea, 20% reduction in lymphocyte level
o Natalizumab (Tysabri™)
- ▪ This IV based infusion is only given to patients with very aggressive disease who have failed lower risk therapies
- ▪ Works by binding to the alpha 4-integrin at the blood brain barrier and in-part blocks lymphocytes from entering into the brain
- ▪ Risky medication, which carries a significant risk for the development of progressive multifocal leukoencephalopathy (PML) which invariably causes death.
Identify other selected demyelinating disease (NOt MS)
Neuromyeltis Optica (Devic’s Disease)
- o It is a relapsing inflammatory demyelinating disease that most commonly affects optic nerves and the spinal cord, leading to sudden vision loss or weakness in one or both eyes, and loss of sensation and bladder function.
- o Does not typically cause the same volume of subcortical white matter lesions
- o Can be assessed by ordering serum NMO IgG antibody
- ▪ Antibody to Aquaporin 4 Chloride Channel
- o Treated with Rituxumab (Rituxan™)
- ▪ The antibody binds to CD20 which is widely expressed on B cells, from early pre-B cells to later in differentiation.
- ▪ Rituximab induces CD20 expressing B-cells to enter apoptosis
Differentiate btw NMO vs MS based on
- Distribution of symptoms and signs
- Attack severity
- Head MRI
- COrd MRI
- CSF cells
- Oligoclonal bands
- Permanent disability
- femal patients
- coexisting autoimmunity
- serum neuromyelitis optica antibody
A 36 y/o woman presents for evaluation of worsened gait over the last 8 years. She has been seen by multiple neurologists and diagnosed with relapsing multiple sclerosis due to history of gait impairment, spasticity, weakness, neurogenic bladder and sensory decrement in the appendages. She has been tried on four different disease modifying therapies all of which appear to have failed given continued accumulation of symptoms and MRI lesions
Primary Progressive MS
- PPMS is a variant of MS that fails to respond to disease modifying therapy
- Patients with this form of the disease account for <10% of all MS cases.
- Generally this is a diagnosis made in retrospect after trying and failing multiple agents
A 32 y/o female with history of RRMS presents to the ED because she awoke with symptoms of right lower extremity numbness and weakness which have been gradually worsening throughout the day. Prior to going to bed she stated she felt fine. She denies pain. She feels as though she is able to void normally. She has been managed on Interferon Beta 1-a (Axonex) for the last 7 years. During the last 2 years she has had three relapses, the last two she has failed to recover completely from her new symptoms. Her last MRI was two years ago.
Physical Exam:
- General Exam: Normal
- Neurologic Exam:
–Mental Status: Normal
–Cranial Nerves: Normal
–Strength: 4/5 weakness in all muscle groups of the right leg.
–Sensory: Decreased sensation to pinprick, temperature, and light touch in the leg
–Coordination: Normal
–Reflexes: 3+ throughout. Right toe is upgoing
–Gait: hemicircumduction of the right leg
Transverse Myelitis
- Transverse Myelitis is demyelination of the spinal cord.
- Transverse myelitis can result in a wide ranging of neurologic symptoms ranging from hemi-sided weakness, sensory deficit (of different types), bowel/bladder dysfunction or some combination of all of the above depending on the location and size of the demyelinating plaque.
A 30 y/o man presents with complaints of 3 days of blurred vision in the left eye only. He has eye pain with extraocular movement. No other neurologic complaints. No past history of neurologic symptomatology. No family history of autoimmune disease.
Physical Exam:
- General Exam: Normal
- Neurologic Exam:
–Mental Status: Normal
–Cranial Nerves: Afferent pupillary defect on the right. Decreased visual acuity with 20/200 vision on the right, normal on the left. Normal eye movements though he does have pain
–Strength: Normal
–Sensory: Normal
–Coordination: Normal
–Reflexes: Normal. Toes are downgoing
–Gait: Normal
Optic Neuritis
- •Optic Neuritis is one of the most common presentations of demyelinating disease
- •Typically presents with complaints of progressive vision loss over days
- –Some liken it to looking through dirty dishwater or a dense screen
- •Typically has mild pain with extraocular movements
- •Usually optic disc swelling can be seen after the first few days of clinical symptoms (sometimes earlier)
A 30 y/o man presents with complaints of 3 days of blurred vision in the left eye only. He has eye pain with extraocular movement. No other neurologic complaints. No past history of neurologic symptomatology. No family history of autoimmune disease.
Physical Exam:
- General Exam: Normal
- Neurologic Exam:
–Mental Status: Normal
–Cranial Nerves: Afferent pupillary defect on the right. Decreased visual acuity with 20/200 vision on the right, normal on the left. Normal eye movements though he does have pain
–Strength: Normal
–Sensory: Normal
–Coordination: Normal
–Reflexes: Normal. Toes are downgoing
–Gait: Normal
MS
–Despite this being the first attack, the revised McDonald Criteria suggests that this patient does now suffer from MS and disease modifying therapy should be initiated.
–If you are not certain then additional work-up can always be obtained.
- A 27-year-old man comes to the office for advice about treatment of his recently diagnosed multiple sclerosis. Three years ago, he had an episode of diplopia that resolved entirely after 2 months. One month ago, he had a mild weakness and numbness of the right leg. MRI of the brain at that time showed multiple cerebral white-matter lesions in a periventricular distribution classic for multiple sclerosis. His leg weakness resolved without treatment. He is now asymptomatic and has a normal neurologic examination. Which of the following is the most appropriate treatment recommendation at this time?
A. High-dose intravenous methylprednisolone
B. Chronic oral prednisone
C. Interferon-beta
D. Observation - A 29-year-old woman comes to the office because of gradual loss of vision in her left eye over 5 days. The problem started as a “smudge” in her central visual field and gradually worsened such that she cannot read with her left eye. She has pain with left eye movements and has difficulty working because of the impairment. Neurologic examination is unremarkable except for her eye findings. Visual acuity is 20/20 in the right eye and 20/400 in the left eye. Visual field testing shows a dense central scotoma on the left. Funduscopic examination is normal. There is a left afferent pupillary defect. MRI of the brain is normal. Which of the following is the best initial course of treatment for this patient?
A. Intravenous methylprednisolone
B. Interferon-beta
C. Glatiramer acetate
D. Aspirin
E. Natalizumab
- C
- A
Overview of Rhabdovirus
Rabies virus, a member of the family Rhabdoviridae, causes a disease of the central nervous system, which often has a protracted incubation period. The prognosis, once disease is apparent, is almost invariably fatal. Rabies in man is usually contracted following the bite by an infected animal or inhalation of aerosol droplets from rabies-infected bats. Further, rabies does not appear to be the result of an encephalitogenic variant of wild-type virus, nor does it result from immunologic defects of the host. On the contrary, rabies has been shown to multiply actively in both neural and extraneural tissues. Further, effective vaccine exists for humans and animals, which may account for the low incidence of clinical rabies in domestic animals and in man.
The purpose of the lecture is to briefly discuss the replication processes of Rhabdoviridae. This replication scheme will serve as the prototype for single stranded, non- segmented,(-) polarity RNA containing viruses. Also, the pathogenesis and control of rabies will be considered. (Remember Influenza virus replication was the model for single-stranded, segmented negative polarity RNA).
- What polarity is the viral genome and how are the progeny RNA formed?
- SS RNA, (-) polarity, nonsegmented
- RNA dependent - RNA polymerase = L + NS protein, other enzymatic activities are associated with this complex
- helical nucleocapsid, RNA + L, NS, N
- bullet-shaped capsid contains 5 structural proteins; L, NS, M, G, N, rhabdoviruses are the only ones with bullet shaped virions
L = large NS = nucleocapsid small
M = matrix G = envelope glycoprotein N = major nucleocapsid
- Posses an envelop; glycoprotein (G) produces neutralizing Ab, acts as hemagglutinin, and inhibits cell processes (may have toxic properties on its own
- Describe replication of rhabdovirus
- Replication and transcription
Replication scheme: Virus particle attaches to receptors on the surface of cells. Receptors vary with cell type; 1) nicotinic acetylcholine receptor (AChR) and 2) neural cell adhesion molecule ( NCAM). The virus enters into the cell by phagocytic engulfment into endosomes and then fusion between the viral envelop and the endosomal membranes, thereby releasing RNA into the cytoplasm of the cell.
Replication of Rhabdoviruses (See Influenza as a prototype replication scheme:
Genome Replication And Transcription:Occur in the cytoplasm:
- Two events must occur relative to the viral genomic RNA.
1. Transcription: The negative (-) polarity genomic RNA must be converted to + polarity mRNA which is translated into viral proteins
Transcription: - viral RNA —> ++++ mRNAs (5 mRNAs formed) Each of the 5 viral mRNAs translated into one of the viral proteins
-
Genome Replication: Many new copies of progeny, negative-polarity genomic RNA must be synthesized. — ++++
- viral RNA —> +++ RNA (RI) —-> — RNA (RI)
Recall: RI is the Replicative intermediate
Viral progeny buds from a site of the plasma membrane to form a bullet shaped virus, which has G glycoprotein extending from it’s envelop on its outer surface
Identify 3 phases of Rabies
1. Incubation phase- prolonged weeks to months
2. Prodromal phase – fever, malaise, headache, sore throat, vomiting, nausea; Viral transport called “Retrograde Axoplasmic)
Rabies virus infects peripheral nerves, replicates in dorsal ganglia and travels up spinal cord to brain
3. Neurological phase- Infection of the brain Rabiesvirus descends to infect eye, glands and visceral organs
- excitement stage - apprehension, fright, hydrophobia (fear of water) (biting stage in dog) - fear of space (air) aerophobia
- manic stage - convulsions, usually death
Other modes of transmission of rabies
Alternative Mode of Transmission: Bats become infected, replication of virus occurs, but no disease results. Virus in saliva and aerosols of saliva are also mode of spread. Most rabies virus infected patients cannot document being bitten by bat.
Animal Bites: Skunks, foxes and raccoons are also primary hosts for rabies virus in US. Dogs are minor sources in US, but are # 1 source in most of the world. Cattle are also infected with rabies in many parts of the world.
Puppy Pregnant Syndrome (Please look it up)
Virus enters host through bite or scratch of rabid animal. The virus is found in animal’s saliva, CNS, urine, lymph, milk, blood. A hunter, who is skinning and dressing an infected animal and accidentally cuts him or herself during the process can acquire the infection.
Rabies initiated by corneal transplants
Details about rabies virus infection
The virus usually remains localized after bite for extended time period. The incubation period is from 10 days to 2 years- usually 2-3 months. This corresponds to the time to multiply in muscle or connective tissue at the bite site and begins to move along the peripheral nerves. The prodromal stage begins (see above) and the virus transcends to the CNS.
Once the CNS is reached, virus multiplies in CNS. Next the virus descends along the peripheral nerves to salivary glands and other organs/tissues. For a rabid dog the virus in the saliva allows it to bite and infect another animal or human. The CNS infection leads to destruction of cortex, midbrain, pons, medulla, posterior horn of SC. What virus infects the anterior horn specifically?
Rabies rarely causes inflammatory lesions
Neutralizing antibody arise late in the course of infection, however, it is too late to prevent the disease course